3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
29
Pain, Postoperative
10
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
8
Stomach Neoplasms
7
Prostatic Neoplasms
6
Lung Neoplasms
6
Pancreatic Neoplasms
5
Melanoma
5
Ovarian Neoplasms
4
Hemorrhage
4
Head and Neck Neoplasms
4
Agnosia
4
Rectal Neoplasms
3
Neurotoxicity Syndromes
3
Nasopharyngeal Carcinoma
3
Myoma
3
Multiple Endocrine Neoplasia Type 1
3
Meningioma
3
Lymphoma, Non-Hodgkin
3
Leiomyoma
3
Glioblastoma
3
Delirium
3
Colonic Neoplasms
3
Chronic Pain
3
Warts
2
Uterine Cervical Neoplasms
2
Stomatitis
2
Skin Neoplasms
2
Interventions
Rituximab
7
Pyridostigmine Bromide
5
Prednisone
5
efgartigimod alfa
4
Hizentra
4
telitacicept
3
Immunoglobulins, Intravenous
3
Cyclophosphamide
3
Azathioprine
3
thymoglobulin
2
fludarabine
2
Thymectomy
2
Steroids
2
Mycophenolic Acid
2
Data Collection
2
Blood Specimen Collection
2
zilucoplan
1
tofacitinib
1
tocilizumab
1
talquetamab
1
sargramostim
1
rozanolixizumab
1
prednylidene
1
gamma-Globulins
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
bu-zhong-yi-qi-tang
1
apraclonidine
1
Walk Test
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Myasthenia Gravis
×
Sodium Chloride
×
Clear all
NCT02950155
2024-10-26
Rinomax
Karolinska Institutet
Phase 3
Completed
47 enrolled
24 charts